{"ticker": {"uuid": "45d51480-8441-4cdb-b554-cb8e9c82703b", "symbol": "CGTX", "name": "Cognition Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit", "summary": "Cognition Therapeutics, Inc. announced that its President and CEO, Lisa Ricciardi, will participate in a fireside chat at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. She will discuss the ongoing START study and the planned Phase 3 trial for zervimesine (CT1812) in", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326105/0/en/cognition-therapeutics-participating-in-fireside-chat-at-b-riley-securities-mind-muscle-vision-summit.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T02:50:36", "published_display": "14 Jul 2026 02:50", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "This article displays financial data for Cognition Therapeutics, Inc. (NASDAQ:CGTX), specifically its enterprise value to EBIT forward. It indicates various data sources and copyright information related to the financial figures presented. The page also includes navigation elemen", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T16:43:30", "published_display": "09 Jul 2026 16:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "The article prominently displays the financial metric \"Enterprise value to revenue forward\" for Cognition Therapeutics, Inc. (NASDAQ: CGTX). It provides a brief financial overview of the company on the Nasdaq Stock Market. The content primarily focuses on the stock's financial da", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T18:40:17", "published_display": "07 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "This article section is about the number of shareholders for Cognition Therapeutics, Inc. (NASDAQ: CGTX). It provides details related to the data for the number of shareholders, indicating the period, value, change, and percentage change. The content also notes that the data is m", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-05T13:40:59", "published_display": "05 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "The article focuses on the \"Price to sales forward\" metric for Cognition Therapeutics, Inc. (NASDAQ:CGTX). It provides market data and financial information for the company, accessible through TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T09:39:41", "published_display": "05 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOV3Ryd3NQZm5tb0dHaGxGdEJ2SzJoaU0xWEg0VWlTSk16ZU9IcEo3RTZ5aEw1LTUyclV4TjYtVHd3YkxQckpjTHBlSndncTNsYjU3OU1XX3ZuV1hKakpwWHhOcGZoeUhZZU1QNy1lN3VLVVRlNU50VnRCV2JjOXNGZ2xjdVhfV3ROcGNrcUtwQVRRU2QtYWJtUVFVYnhBeE5Mbmc?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T08:38:42+00:00", "published_display": "05 Jul 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Cognition Therapeutics, Inc.'s SEC filings and other important company documents, including earnings reports, conference transcripts, and corporate presentations. These documents outline the company's financial performance, operationa", "url": "https://www.tradingview.com/symbols/BOATS-CGTX/documents/", "source_name": "TradingView", "published_at": "2026-07-02T06:10:43", "published_display": "02 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment", "summary": "H.C. Wainwright maintained a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ:CGTX) after the company announced positive FDA feedback regarding its drug development program for psychosis associated with dementia with Lewy bodies. The FDA agreed that psychosis c", "url": "https://za.investing.com/news/stock-market-news/hc-wainwright-reiterates-cognition-therapeutics-stock-rating-on-fda-alignment-93CH-4351740", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T13:54:00", "published_display": "01 Jul 2026 13:54", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate", "summary": "The article discusses Cognition Therapeutics' (NASDAQ:CGTX) cash burn rate, highlighting its significant spending on operating expenses and research and development relative to its cash reserves. It notes the company's strong cash position but emphasizes the need for efficient ca", "url": "https://www.moomoo.com/news/post/72197287/we-re-keeping-an-eye-on-cognition-therapeutics-nasdaq-cgtx", "source_name": "Moomoo", "published_at": "2026-06-30T09:39:50", "published_display": "30 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell Microcap Index", "summary": "Cognition Therapeutics, Inc. (NasdaqCM: CGTX) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina,", "url": "https://www.marketscreener.com/news/cognition-therapeutics-inc-nasdaqcm-cgtx-added-to-russell-microcap-index-ce7f5fdedd89fe26", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:10:27", "published_display": "29 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3", "summary": "H.C. Wainwright has reiterated its Buy rating for Cognition Therapeutics (CGTX.US) and maintained a target price of $3. This indicates the firm's continued positive outlook on the company's stock based on its analysis.", "url": "https://www.moomoo.com/news/post/72040879/hc-wainwright-maintains-cognition-therapeutics-cgtxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-26T08:40:45", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGTX)", "summary": "This article provides an overview of Cognition Therapeutics, Inc. (NASDAQ: CGTX), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights key financial metrics, upcoming earnings reports, and answers frequently asked questio", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:58", "published_display": "25 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes", "summary": "Cognition Therapeutics has received positive feedback from the FDA regarding key aspects of a pivotal study for zervimesine (CT1812) in treating psychosis associated with dementia with Lewy bodies (DLB). The FDA agreed that DLB psychosis could be an approvable outcome, and the co", "url": "https://finance.yahoo.com/healthcare/articles/cognition-therapeutics-aligns-key-aspects-113000634.html", "source_name": "Market source", "published_at": "2026-06-25T10:09:54", "published_display": "25 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA says DLB psychosis could be approvable in Cognition trial plan", "summary": "Cognition Therapeutics (NASDAQ: CGTX) announced that the FDA has agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome, aligning on key aspects of a pivotal Phase 3 trial for zervimesine (CT1812). The registrational program is expect", "url": "https://www.stocktitan.net/news/CGTX/cognition-therapeutics-aligns-on-key-aspects-of-pivotal-study-for-dnri7am2d41x.html", "source_name": "Stock Titan", "published_at": "2026-06-24T18:22:14", "published_display": "24 Jun 2026 18:22", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Agrees With FDA on Phase 3 Trial Framework for Psychosis Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cognition-therapeutics-agrees-fda-phase-122300519.html", "source_name": "MT Newswires", "published_at": "2026-06-24T12:23:00+00:00", "published_display": "24 Jun 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis \u2013 But CGTX Stock Just Crashed 33%", "summary": "Cognition Therapeutics received positive feedback from the FDA regarding its planned Phase 3 study for Zervimesine in DLB psychosis, with the trial expected to begin in mid-2027. Despite this, the company's shares dropped over 33% due to investor concerns about the lengthy timeli", "url": "https://stocktwits.com/news-articles/markets/equity/why-cgtx-stock-fell-despite-fda-feedback/cZKyWX0R7fq", "source_name": "Stocktwits", "published_at": "2026-06-24T11:47:00", "published_display": "24 Jun 2026 11:47", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition, FDA agree on late-stage trial for dementia therapy", "summary": "Cognition Therapeutics (CGTX) saw a premarket increase of ~5% after announcing alignment with the FDA on key aspects of a late-stage trial. The trial will test its lead asset, zervimesine, for a specific form of dementia. This agreement marks a significant step forward for the co", "url": "https://seekingalpha.com/news/4606603-cognition-fda-agree-late-stage-trial-dementia-therapy", "source_name": "Seeking Alpha", "published_at": "2026-06-24T11:41:14", "published_display": "24 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics (NASDAQ: CGTX) wins FDA alignment on pivotal DLB psychosis study for zervimesine", "summary": "Cognition Therapeutics announced FDA alignment on key aspects of a pivotal Phase 3 trial for zervimesine (CT1812) to treat psychosis in dementia with Lewy bodies (DLB). The FDA agreed that DLB psychosis is an approvable outcome, paving the way for a New Drug Application. The stud", "url": "https://www.stocktitan.net/sec-filings/CGTX/8-k-cognition-therapeutics-inc-reports-material-event-d228576c8133.html", "source_name": "Stock Titan", "published_at": "2026-06-24T11:41:14", "published_display": "24 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Secures FDA Alignment for Phase 3 Zervimesine Trial in DLB Psychosis", "summary": "Cognition Therapeutics announced that the FDA has agreed on the pivotal trial design for its candidate treatment, zervimesine, for psychosis associated with dementia with Lewy bodies (DLB). This alignment marks a significant step towards regulatory approval, addressing an urgent ", "url": "https://www.quiverquant.com/news/Cognition+Therapeutics+Secures+FDA+Alignment+for+Phase+3+Zervimesine+Trial+in+DLB+Psychosis", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T11:40:00", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZnNsMDB0SGg3ZjdLTGF3S0ZfblFsbE9xWV83S0tneFFJUms5NzBfMThjdk94aEdVV3NTc0k1OFJVS3RGZGRLVm1wUmRQakZnZFFyMFNhSlJRWW4tcTg3WVp4WEZRTkdUVllPYUtSUWhjeXVRSjBnNXgtaWdqNmdQcm5PWHEtLXdxZ2NLTzF3ZllfMGNlMUJ3bVNMS05GcmZTVGo0Ql9pMTQ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Aligns on Key Aspects of Pivotal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugJBVV95cUxOZDRpV2haRUxTX1Rjc0hNNmUxMm5QNWNkRDV3TGVoN1pLUk5ScldrVGdFb1FndWZURWdCaFR6MEJ1YUZ1VTVVbl9lclNleHV1c3dJZWZZZDRFeHB3V19lWnhzLUZXNGlMdXdaYm9RZ1VQYTlFMWlLeElfQUt5NkNYSHRmOTJ2RmFqX1NJaFY1LUNCTU9IcnJkTFZPU2stN1lJNXM2YjB3NlJKamxZQVFFLXAxZTNob3FGRTUtRUZVRC1jcndnM2NBdmMxUk1aa3FaNHFmS21ZLWVpOHJJMzVKeldwNzNMSEVkQ2ZzYUVfRVJpX25GbWxCTHlZYmxONW1JXzhsblBnLVZBcHJoYjgyWWxKZ3NvLXRmaWx1WlFMenRrblc2NU5FVDhEYmZQSnlGVWJfdzRONHBJdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics stock rises on FDA trial alignment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxONDNINlJOeGROeUFDNElhTHVMeXlHQkRRRFV6d1hENUZiblp5emlTSlJvVDJoS20tVGxaQjBmM0dDNFMyM2dJVnFjQUJ5SmNyTzBaMmhSMUxSMTVtd3FCZ1NyNzVJejlMNjJ0VDhpeFc4RzNmX2w0aEZXUjRzNnl1S2k2cVQ3cHJQNWZNcUV0VGI5ajF2X3dseWJJTWIxOVVMQXJQVV94R081eE1aZ19ZWTZWT0tjSHpJTTZR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14A Cognition Therapeutics Inc For: 23 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form DEF 14A by Cognition Therapeutics Inc. for June 23. It provides no further details about the filing but includes various market data and other news headlines.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-cognition-therapeutics-inc-for-23-june-93CH-2571331", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T02:40:57", "published_display": "24 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Cognition Therapeutics (CGTX) awarded 25,000 RSUs", "summary": "Cognition Therapeutics director Jack A. Khattar was granted 25,000 restricted stock units (RSUs) as an equity award. These RSUs, valued at $0.00 each for the grant, will vest in full on the earlier of June 17, 2027, or the company's next annual stockholders' meeting, provided he ", "url": "https://www.stocktitan.net/sec-filings/CGTX/form-4-cognition-therapeutics-inc-insider-trading-activity-99269369c200.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:10:44", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant lifts Cognition Therapeutics (CGTX) director Peggy Wallace\u2019s holdings", "summary": "Cognition Therapeutics director Peggy Wallace received a grant of 25,000 Restricted Stock Units (RSUs) as compensation for her board service. These RSUs, which are a contingent right to receive common stock, will vest in full by June 17, 2027, or the company's next annual meeting", "url": "https://www.stocktitan.net/sec-filings/CGTX/form-4-cognition-therapeutics-inc-insider-trading-activity-57dfb209f3e1.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:10:43", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Cognition Therapeutics (CGTX) granted 25,000 RSUs", "summary": "Cognition Therapeutics director Ellen B. Richstone was granted 25,000 restricted stock units (RSUs) as compensation, not through an open-market trade. These RSUs, which vest on June 17, 2027, or the company's next annual stockholder meeting contingent on her continued board servi", "url": "https://www.stocktitan.net/sec-filings/CGTX/form-4-cognition-therapeutics-inc-insider-trading-activity-2d5da6aa0c7c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:10:43", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] COGNITION THERAPEUTICS INC Insider Trading Activity", "summary": "This article reports on insider trading activity at COGNITION THERAPEUTICS INC (CGTX) based on a Form 4 filing. Director Aaron G.L. Fletcher was granted 25,000 Restricted Stock Units (RSUs) which vest on the earlier of June 17, 2027, or the company's next annual stockholder meeti", "url": "https://www.stocktitan.net/sec-filings/CGTX/form-4-cognition-therapeutics-inc-insider-trading-activity-cc98c4be7fff.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:43", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news", "summary": "H.C. Wainwright maintained a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ:CGTX) after the company secured a Notice of Allowance for a patent covering a polymorphic crystalline form of its lead drug candidate, zervimesine. This patent provides protection thr", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-cognition-therapeutics-stock-rating-on-patent-news-93CH-4752433", "source_name": "Investing.com", "published_at": "2026-06-22T12:09:56", "published_display": "22 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Cognition Therapeutics (CGTX) receives 25,000 RSUs and holds 73,500 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNDkwQUpKanFHREtTTmdiZkF3RjVBcjc4ZWlEQVhmU08tbm5oX3h2WGJUaGJKM3pZcENSZGU5aFdiQVRjRld5WHUybkN1aXplLUtKbzRIcl9hOUIyaWROeEpib2poZ056WGxDZktXVHFRblVOMG1xSTNVWEk3U3dqSzJfU0V1UFU5Ti1lRE5mMmFNZWUxNS1jRllib20xajVsV0kwaFJnNktPTmNUT29VQkNpT3JFbGtCR2FoOQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045", "summary": "Cognition Therapeutics has received a Notice of Allowance for a new composition of matter patent for a polymorphic crystalline form of its lead drug candidate, zervimesine (CT1812). This patent will extend protection for the drug through 2045, potentially to 2050 with extensions.", "url": "https://finance.yahoo.com/healthcare/articles/cognition-therapeutics-announces-composition-matter-113000263.html", "source_name": "Market source", "published_at": "2026-06-20T23:11:00", "published_display": "20 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor", "summary": "Cognition Therapeutics shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors to serve until the 2029 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year. An analyst rating indic", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CGTX-Q/pressreleases/2555169/cognition-therapeutics-shareholders-elect-directors-ratify-auditor/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T05:11:06", "published_display": "20 Jun 2026 05:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com", "summary": "Cognition Therapeutics Inc. (NASDAQ: CGTX) announced the results of its annual meeting, where shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent register", "url": "https://ng.investing.com/news/sec-filings/cognition-therapeutics-elects-directors-and-ratifies-auditor-at-annual-meeting-93CH-2565243", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T17:10:11", "published_display": "18 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics elects directors and ratifies auditor at annual meeting", "summary": "Cognition Therapeutics, Inc. held its annual meeting where shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors. Stockholders also ratified Ernst & Young LLP as the independent auditor for the 2026 fiscal year. These decisions were announced follow", "url": "https://m.uk.investing.com/news/sec-filings/cognition-therapeutics-elects-directors-and-ratifies-auditor-at-annual-meeting-93CH-4735352?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T16:40:20", "published_display": "18 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Receives Patent Allowance for Polymorphic Crystalline Form of Zervimesine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cognition-therapeutics-receives-patent-allowance-121923999.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:19:23+00:00", "published_display": "16 Jun 2026 12:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Announces New Composition of Matter", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAJBVV95cUxQX2lYMGNpYUVpakVYOVpPX0xiOHRqLWUzRVRHdTc5ZmlUX3Y5Rk1TRVk5YmJyQko0akNwUGh6dUtpcmU5eXJMNHU4SS1URklmemVMUVZ4R0ZWVjhENVpnSUFjNmZxQkFHZ3R1ODdEY0xFZUdHbjl3TUlEVlYwbTY3SEtvekRJX09QQ1ZDQVlvQmNMZGFHTEY0aVpyVzdwQ1NGUGozb0JIbkwxVzdxWmRzNDFRYkpJQmROdnZ6ZjJWN3NZOGJGR0htTFM3b2RVX2ZJajBqUVVsTS1neTVzdjI4VnkxQW9NclhlZ2l1cjFIVnJ0OG9YRlplMTBOMVpMbzA4NXNsTWZsN3FUS0Q2MW5jRXd5QWNzNzBUZ3NpNmVRd1RQUGV2c2dMUGdFNFV1RTlnM0VVN1V1akY2VklS?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics receives patent allowance for zervimesine By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQTVU3Sk5pZlhld1JsVGctWFVFamo1eXU1SkVDdnpTODB4TFRNaHRfalo4d0k3Nl9OdHduTUlDbm1kNmJhMHk1WnNpVUFlcTgxVThyRWQ2UWp1Mm5TSjQyazRUNkJLNUVTX3BKNHFqOGhjeFhOZk8yU3V2UmNBVUx2eXE5ejRKVjlialdVWHFDOWtzYVI0cXJ6dVcxRjVxWVNBdnIydExyVktQeVVTdkdZSnBNNk5JMl9XME5oYUNqb1FKMWc?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQdUtBcS1YV25LcVhTTGh3SG5KVWRvTE9HZDVYNzZjcWsyLXVrd0h3b21NNy1xNlhMX19wdDJGYmtJUUdFMTNBSFlqMTg4eEhSN0lPWHZrWXFNMl9oOC1LR25vZFZhRi15WldPZGtxQUFfM056YWk0Tk93UDNsbzlMNVEzTHZDWDVHLW5nM3o0eTlhajV5WjRjNjM5ejJvUy1qZTdheEtiVzhLZjg?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Participating in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cognition-therapeutics-participating-upcoming-investor-113000066.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T11:30:00+00:00", "published_display": "01 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cognition-therapeutics-completes-meeting-fda-113000783.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T11:30:00+00:00", "published_display": "21 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Completes Meeting with FDA for", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxQbzJUdVZzbm1xVF9rVEtDMkxrQTVXUDQ0Tm5iMG1HQ0dqS1dHbXJZU1dSaWRXWk1fSlRhT1NkaWJ6Q0FuOGx5am42dlp1aURGR1NYVkxYN3hCOW9fOG5yMHdCZ25NcF94cXIwSUhMOE56NGt6SXR1aC1LVXVIYnN1UGV3Yl84eDZZb19fZ1FJUC1xVGJSUk9odDVNQWFmQXFXTUN2Y1k2Y1JWU3FHSFBJRTA0VjZvdGU1RnRMcGVxTDRVeG02WVNOOWF3TXFaaHYyY2ZYRGZjRFppdzBmQkYxRDFOZG5qMVl1TFhza1p4UmFTaG1hZ2JPaEVROVBBYlpBYnlPczJqSS1RSmhOQktJd1I1Wlk5NzQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA, Cognition discuss next trial for Lewy body dementia psychosis drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVlRPZ1p5bjNmTUJSWFpPQW1FUTlYVUNqRml3dGF2UVBNM2QySXBnZnd1OG9WWVRsdEVqTWhERnpxNjZldmprZUVOdUVvYjJ5VlJpRUE1TlNjLXpzLUpLaHkzRVVFbVRxX2RhQl9iYW02Nmh4X0FkLUo2Uld5dzFBanM2MmptZFRnc2E3eFJTYXhoRjNnMHViMW13T2Z5SV81aUtMaG9QaVE5Z2dPWHNpdnlwQWpzYWVoM3B1SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics sets March 26 webcast on 2025 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNdWNwZmc4NE9xdU5DSktBSjlCdWFGLUpJaVlTWlhSc0RKTlJzMHRsNVZST1JDQnduTV9sMlZIWmJEY0NGZG5YNmpqM3puWDNsMW5LOEROZ1ppTzkwOTVOeFpZMlVNcEFHLWdGcFlrMTZFRDB2aGNIWkZ6bGpCMnhjVEhwb19ZYV9fZkZPR1MwZXFNbUU3SXB6NVlQVF9sTkhNWDJCVHVZTjBWa1ZEbzBfVERURFZiMXVzbnh0Rg?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics, Inc. Achieves 75% Enrollment in Phase 2 START Study for Early Alzheimer\u2019s Disease Treatment | CGTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQM2hNbllkckxRVG1rSVc5QVZHSnJvYk4zbDdnZVB0RmwtWWxhNDdpTXcybmdpYlVZeG9UOVJ0aVdRZ1hiVmxUcGFNTUM4STdLVFIwQW8wdWFxVmc2ZmJ5YjY0OUlUbGZWenR4aVdhdnJBcVluQmFGdWVDV0pPUm9hMXpHd09sTC1yQzM2Y3M5ZkxIc1ZXaDdZTGFWWUc5RkdRS3dMY0xFZ19GaXBkanpGZWZIcXd2SjZiUUN5a0pWSGltLWhObVZYWS1YUWU4NzB0ZEd6OEItb2R4OU5Eckw3dGR5WURaY29fSllFQkUxMUJzUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-09-03T07:00:00+00:00", "published_display": "03 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit", "summary": "Cognition Therapeutics, Inc. announced that its President and CEO, Lisa Ricciardi, will participate in a fireside chat at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. She will discuss the ongoing START study and the planned Phase 3 trial for zervimesine (CT1812) in", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326105/0/en/cognition-therapeutics-participating-in-fireside-chat-at-b-riley-securities-mind-muscle-vision-summit.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T02:50:36", "published_display": "14 Jul 2026 02:50", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "This article displays financial data for Cognition Therapeutics, Inc. (NASDAQ:CGTX), specifically its enterprise value to EBIT forward. It indicates various data sources and copyright information related to the financial figures presented. The page also includes navigation elemen", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T16:43:30", "published_display": "09 Jul 2026 16:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "The article prominently displays the financial metric \"Enterprise value to revenue forward\" for Cognition Therapeutics, Inc. (NASDAQ: CGTX). It provides a brief financial overview of the company on the Nasdaq Stock Market. The content primarily focuses on the stock's financial da", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T18:40:17", "published_display": "07 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "This article section is about the number of shareholders for Cognition Therapeutics, Inc. (NASDAQ: CGTX). It provides details related to the data for the number of shareholders, indicating the period, value, change, and percentage change. The content also notes that the data is m", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-05T13:40:59", "published_display": "05 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "The article focuses on the \"Price to sales forward\" metric for Cognition Therapeutics, Inc. (NASDAQ:CGTX). It provides market data and financial information for the company, accessible through TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T09:39:41", "published_display": "05 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cognition Therapeutics, Inc. \u2013 NASDAQ:CGTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOV3Ryd3NQZm5tb0dHaGxGdEJ2SzJoaU0xWEg0VWlTSk16ZU9IcEo3RTZ5aEw1LTUyclV4TjYtVHd3YkxQckpjTHBlSndncTNsYjU3OU1XX3ZuV1hKakpwWHhOcGZoeUhZZU1QNy1lN3VLVVRlNU50VnRCV2JjOXNGZ2xjdVhfV3ROcGNrcUtwQVRRU2QtYWJtUVFVYnhBeE5Mbmc?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T08:38:42+00:00", "published_display": "05 Jul 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Cognition Therapeutics, Inc.'s SEC filings and other important company documents, including earnings reports, conference transcripts, and corporate presentations. These documents outline the company's financial performance, operationa", "url": "https://www.tradingview.com/symbols/BOATS-CGTX/documents/", "source_name": "TradingView", "published_at": "2026-07-02T06:10:43", "published_display": "02 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment", "summary": "H.C. Wainwright maintained a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ:CGTX) after the company announced positive FDA feedback regarding its drug development program for psychosis associated with dementia with Lewy bodies. The FDA agreed that psychosis c", "url": "https://za.investing.com/news/stock-market-news/hc-wainwright-reiterates-cognition-therapeutics-stock-rating-on-fda-alignment-93CH-4351740", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T13:54:00", "published_display": "01 Jul 2026 13:54", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate", "summary": "The article discusses Cognition Therapeutics' (NASDAQ:CGTX) cash burn rate, highlighting its significant spending on operating expenses and research and development relative to its cash reserves. It notes the company's strong cash position but emphasizes the need for efficient ca", "url": "https://www.moomoo.com/news/post/72197287/we-re-keeping-an-eye-on-cognition-therapeutics-nasdaq-cgtx", "source_name": "Moomoo", "published_at": "2026-06-30T09:39:50", "published_display": "30 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell Microcap Index", "summary": "Cognition Therapeutics, Inc. (NasdaqCM: CGTX) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina,", "url": "https://www.marketscreener.com/news/cognition-therapeutics-inc-nasdaqcm-cgtx-added-to-russell-microcap-index-ce7f5fdedd89fe26", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:10:27", "published_display": "29 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3", "summary": "H.C. Wainwright has reiterated its Buy rating for Cognition Therapeutics (CGTX.US) and maintained a target price of $3. This indicates the firm's continued positive outlook on the company's stock based on its analysis.", "url": "https://www.moomoo.com/news/post/72040879/hc-wainwright-maintains-cognition-therapeutics-cgtxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-26T08:40:45", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGTX)", "summary": "This article provides an overview of Cognition Therapeutics, Inc. (NASDAQ: CGTX), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights key financial metrics, upcoming earnings reports, and answers frequently asked questio", "url": "https://www.tradingview.com/symbols/NASDAQ-CGTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:58", "published_display": "25 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes", "summary": "Cognition Therapeutics has received positive feedback from the FDA regarding key aspects of a pivotal study for zervimesine (CT1812) in treating psychosis associated with dementia with Lewy bodies (DLB). The FDA agreed that DLB psychosis could be an approvable outcome, and the co", "url": "https://finance.yahoo.com/healthcare/articles/cognition-therapeutics-aligns-key-aspects-113000634.html", "source_name": "Market source", "published_at": "2026-06-25T10:09:54", "published_display": "25 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA says DLB psychosis could be approvable in Cognition trial plan", "summary": "Cognition Therapeutics (NASDAQ: CGTX) announced that the FDA has agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome, aligning on key aspects of a pivotal Phase 3 trial for zervimesine (CT1812). The registrational program is expect", "url": "https://www.stocktitan.net/news/CGTX/cognition-therapeutics-aligns-on-key-aspects-of-pivotal-study-for-dnri7am2d41x.html", "source_name": "Stock Titan", "published_at": "2026-06-24T18:22:14", "published_display": "24 Jun 2026 18:22", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Agrees With FDA on Phase 3 Trial Framework for Psychosis Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cognition-therapeutics-agrees-fda-phase-122300519.html", "source_name": "MT Newswires", "published_at": "2026-06-24T12:23:00+00:00", "published_display": "24 Jun 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis \u2013 But CGTX Stock Just Crashed 33%", "summary": "Cognition Therapeutics received positive feedback from the FDA regarding its planned Phase 3 study for Zervimesine in DLB psychosis, with the trial expected to begin in mid-2027. Despite this, the company's shares dropped over 33% due to investor concerns about the lengthy timeli", "url": "https://stocktwits.com/news-articles/markets/equity/why-cgtx-stock-fell-despite-fda-feedback/cZKyWX0R7fq", "source_name": "Stocktwits", "published_at": "2026-06-24T11:47:00", "published_display": "24 Jun 2026 11:47", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition, FDA agree on late-stage trial for dementia therapy", "summary": "Cognition Therapeutics (CGTX) saw a premarket increase of ~5% after announcing alignment with the FDA on key aspects of a late-stage trial. The trial will test its lead asset, zervimesine, for a specific form of dementia. This agreement marks a significant step forward for the co", "url": "https://seekingalpha.com/news/4606603-cognition-fda-agree-late-stage-trial-dementia-therapy", "source_name": "Seeking Alpha", "published_at": "2026-06-24T11:41:14", "published_display": "24 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics (NASDAQ: CGTX) wins FDA alignment on pivotal DLB psychosis study for zervimesine", "summary": "Cognition Therapeutics announced FDA alignment on key aspects of a pivotal Phase 3 trial for zervimesine (CT1812) to treat psychosis in dementia with Lewy bodies (DLB). The FDA agreed that DLB psychosis is an approvable outcome, paving the way for a New Drug Application. The stud", "url": "https://www.stocktitan.net/sec-filings/CGTX/8-k-cognition-therapeutics-inc-reports-material-event-d228576c8133.html", "source_name": "Stock Titan", "published_at": "2026-06-24T11:41:14", "published_display": "24 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Secures FDA Alignment for Phase 3 Zervimesine Trial in DLB Psychosis", "summary": "Cognition Therapeutics announced that the FDA has agreed on the pivotal trial design for its candidate treatment, zervimesine, for psychosis associated with dementia with Lewy bodies (DLB). This alignment marks a significant step towards regulatory approval, addressing an urgent ", "url": "https://www.quiverquant.com/news/Cognition+Therapeutics+Secures+FDA+Alignment+for+Phase+3+Zervimesine+Trial+in+DLB+Psychosis", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T11:40:00", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZnNsMDB0SGg3ZjdLTGF3S0ZfblFsbE9xWV83S0tneFFJUms5NzBfMThjdk94aEdVV3NTc0k1OFJVS3RGZGRLVm1wUmRQakZnZFFyMFNhSlJRWW4tcTg3WVp4WEZRTkdUVllPYUtSUWhjeXVRSjBnNXgtaWdqNmdQcm5PWHEtLXdxZ2NLTzF3ZllfMGNlMUJ3bVNMS05GcmZTVGo0Ql9pMTQ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Aligns on Key Aspects of Pivotal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugJBVV95cUxOZDRpV2haRUxTX1Rjc0hNNmUxMm5QNWNkRDV3TGVoN1pLUk5ScldrVGdFb1FndWZURWdCaFR6MEJ1YUZ1VTVVbl9lclNleHV1c3dJZWZZZDRFeHB3V19lWnhzLUZXNGlMdXdaYm9RZ1VQYTlFMWlLeElfQUt5NkNYSHRmOTJ2RmFqX1NJaFY1LUNCTU9IcnJkTFZPU2stN1lJNXM2YjB3NlJKamxZQVFFLXAxZTNob3FGRTUtRUZVRC1jcndnM2NBdmMxUk1aa3FaNHFmS21ZLWVpOHJJMzVKeldwNzNMSEVkQ2ZzYUVfRVJpX25GbWxCTHlZYmxONW1JXzhsblBnLVZBcHJoYjgyWWxKZ3NvLXRmaWx1WlFMenRrblc2NU5FVDhEYmZQSnlGVWJfdzRONHBJdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics stock rises on FDA trial alignment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxONDNINlJOeGROeUFDNElhTHVMeXlHQkRRRFV6d1hENUZiblp5emlTSlJvVDJoS20tVGxaQjBmM0dDNFMyM2dJVnFjQUJ5SmNyTzBaMmhSMUxSMTVtd3FCZ1NyNzVJejlMNjJ0VDhpeFc4RzNmX2w0aEZXUjRzNnl1S2k2cVQ3cHJQNWZNcUV0VGI5ajF2X3dseWJJTWIxOVVMQXJQVV94R081eE1aZ19ZWTZWT0tjSHpJTTZR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14A Cognition Therapeutics Inc For: 23 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form DEF 14A by Cognition Therapeutics Inc. for June 23. It provides no further details about the filing but includes various market data and other news headlines.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-cognition-therapeutics-inc-for-23-june-93CH-2571331", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T02:40:57", "published_display": "24 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Cognition Therapeutics (CGTX) awarded 25,000 RSUs", "summary": "Cognition Therapeutics director Jack A. Khattar was granted 25,000 restricted stock units (RSUs) as an equity award. These RSUs, valued at $0.00 each for the grant, will vest in full on the earlier of June 17, 2027, or the company's next annual stockholders' meeting, provided he ", "url": "https://www.stocktitan.net/sec-filings/CGTX/form-4-cognition-therapeutics-inc-insider-trading-activity-99269369c200.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:10:44", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant lifts Cognition Therapeutics (CGTX) director Peggy Wallace\u2019s holdings", "summary": "Cognition Therapeutics director Peggy Wallace received a grant of 25,000 Restricted Stock Units (RSUs) as compensation for her board service. These RSUs, which are a contingent right to receive common stock, will vest in full by June 17, 2027, or the company's next annual meeting", "url": "https://www.stocktitan.net/sec-filings/CGTX/form-4-cognition-therapeutics-inc-insider-trading-activity-57dfb209f3e1.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:10:43", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Cognition Therapeutics (CGTX) granted 25,000 RSUs", "summary": "Cognition Therapeutics director Ellen B. Richstone was granted 25,000 restricted stock units (RSUs) as compensation, not through an open-market trade. These RSUs, which vest on June 17, 2027, or the company's next annual stockholder meeting contingent on her continued board servi", "url": "https://www.stocktitan.net/sec-filings/CGTX/form-4-cognition-therapeutics-inc-insider-trading-activity-2d5da6aa0c7c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:10:43", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] COGNITION THERAPEUTICS INC Insider Trading Activity", "summary": "This article reports on insider trading activity at COGNITION THERAPEUTICS INC (CGTX) based on a Form 4 filing. Director Aaron G.L. Fletcher was granted 25,000 Restricted Stock Units (RSUs) which vest on the earlier of June 17, 2027, or the company's next annual stockholder meeti", "url": "https://www.stocktitan.net/sec-filings/CGTX/form-4-cognition-therapeutics-inc-insider-trading-activity-cc98c4be7fff.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:43", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news", "summary": "H.C. Wainwright maintained a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ:CGTX) after the company secured a Notice of Allowance for a patent covering a polymorphic crystalline form of its lead drug candidate, zervimesine. This patent provides protection thr", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-cognition-therapeutics-stock-rating-on-patent-news-93CH-4752433", "source_name": "Investing.com", "published_at": "2026-06-22T12:09:56", "published_display": "22 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Cognition Therapeutics (CGTX) receives 25,000 RSUs and holds 73,500 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNDkwQUpKanFHREtTTmdiZkF3RjVBcjc4ZWlEQVhmU08tbm5oX3h2WGJUaGJKM3pZcENSZGU5aFdiQVRjRld5WHUybkN1aXplLUtKbzRIcl9hOUIyaWROeEpib2poZ056WGxDZktXVHFRblVOMG1xSTNVWEk3U3dqSzJfU0V1UFU5Ti1lRE5mMmFNZWUxNS1jRllib20xajVsV0kwaFJnNktPTmNUT29VQkNpT3JFbGtCR2FoOQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045", "summary": "Cognition Therapeutics has received a Notice of Allowance for a new composition of matter patent for a polymorphic crystalline form of its lead drug candidate, zervimesine (CT1812). This patent will extend protection for the drug through 2045, potentially to 2050 with extensions.", "url": "https://finance.yahoo.com/healthcare/articles/cognition-therapeutics-announces-composition-matter-113000263.html", "source_name": "Market source", "published_at": "2026-06-20T23:11:00", "published_display": "20 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor", "summary": "Cognition Therapeutics shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors to serve until the 2029 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year. An analyst rating indic", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CGTX-Q/pressreleases/2555169/cognition-therapeutics-shareholders-elect-directors-ratify-auditor/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T05:11:06", "published_display": "20 Jun 2026 05:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com", "summary": "Cognition Therapeutics Inc. (NASDAQ: CGTX) announced the results of its annual meeting, where shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent register", "url": "https://ng.investing.com/news/sec-filings/cognition-therapeutics-elects-directors-and-ratifies-auditor-at-annual-meeting-93CH-2565243", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T17:10:11", "published_display": "18 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics elects directors and ratifies auditor at annual meeting", "summary": "Cognition Therapeutics, Inc. held its annual meeting where shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors. Stockholders also ratified Ernst & Young LLP as the independent auditor for the 2026 fiscal year. These decisions were announced follow", "url": "https://m.uk.investing.com/news/sec-filings/cognition-therapeutics-elects-directors-and-ratifies-auditor-at-annual-meeting-93CH-4735352?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T16:40:20", "published_display": "18 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Receives Patent Allowance for Polymorphic Crystalline Form of Zervimesine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cognition-therapeutics-receives-patent-allowance-121923999.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:19:23+00:00", "published_display": "16 Jun 2026 12:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Announces New Composition of Matter", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAJBVV95cUxQX2lYMGNpYUVpakVYOVpPX0xiOHRqLWUzRVRHdTc5ZmlUX3Y5Rk1TRVk5YmJyQko0akNwUGh6dUtpcmU5eXJMNHU4SS1URklmemVMUVZ4R0ZWVjhENVpnSUFjNmZxQkFHZ3R1ODdEY0xFZUdHbjl3TUlEVlYwbTY3SEtvekRJX09QQ1ZDQVlvQmNMZGFHTEY0aVpyVzdwQ1NGUGozb0JIbkwxVzdxWmRzNDFRYkpJQmROdnZ6ZjJWN3NZOGJGR0htTFM3b2RVX2ZJajBqUVVsTS1neTVzdjI4VnkxQW9NclhlZ2l1cjFIVnJ0OG9YRlplMTBOMVpMbzA4NXNsTWZsN3FUS0Q2MW5jRXd5QWNzNzBUZ3NpNmVRd1RQUGV2c2dMUGdFNFV1RTlnM0VVN1V1akY2VklS?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics receives patent allowance for zervimesine By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQTVU3Sk5pZlhld1JsVGctWFVFamo1eXU1SkVDdnpTODB4TFRNaHRfalo4d0k3Nl9OdHduTUlDbm1kNmJhMHk1WnNpVUFlcTgxVThyRWQ2UWp1Mm5TSjQyazRUNkJLNUVTX3BKNHFqOGhjeFhOZk8yU3V2UmNBVUx2eXE5ejRKVjlialdVWHFDOWtzYVI0cXJ6dVcxRjVxWVNBdnIydExyVktQeVVTdkdZSnBNNk5JMl9XME5oYUNqb1FKMWc?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQdUtBcS1YV25LcVhTTGh3SG5KVWRvTE9HZDVYNzZjcWsyLXVrd0h3b21NNy1xNlhMX19wdDJGYmtJUUdFMTNBSFlqMTg4eEhSN0lPWHZrWXFNMl9oOC1LR25vZFZhRi15WldPZGtxQUFfM056YWk0Tk93UDNsbzlMNVEzTHZDWDVHLW5nM3o0eTlhajV5WjRjNjM5ejJvUy1qZTdheEtiVzhLZjg?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Participating in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cognition-therapeutics-participating-upcoming-investor-113000066.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T11:30:00+00:00", "published_display": "01 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cognition-therapeutics-completes-meeting-fda-113000783.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T11:30:00+00:00", "published_display": "21 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics Completes Meeting with FDA for", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxQbzJUdVZzbm1xVF9rVEtDMkxrQTVXUDQ0Tm5iMG1HQ0dqS1dHbXJZU1dSaWRXWk1fSlRhT1NkaWJ6Q0FuOGx5am42dlp1aURGR1NYVkxYN3hCOW9fOG5yMHdCZ25NcF94cXIwSUhMOE56NGt6SXR1aC1LVXVIYnN1UGV3Yl84eDZZb19fZ1FJUC1xVGJSUk9odDVNQWFmQXFXTUN2Y1k2Y1JWU3FHSFBJRTA0VjZvdGU1RnRMcGVxTDRVeG02WVNOOWF3TXFaaHYyY2ZYRGZjRFppdzBmQkYxRDFOZG5qMVl1TFhza1p4UmFTaG1hZ2JPaEVROVBBYlpBYnlPczJqSS1RSmhOQktJd1I1Wlk5NzQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA, Cognition discuss next trial for Lewy body dementia psychosis drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVlRPZ1p5bjNmTUJSWFpPQW1FUTlYVUNqRml3dGF2UVBNM2QySXBnZnd1OG9WWVRsdEVqTWhERnpxNjZldmprZUVOdUVvYjJ5VlJpRUE1TlNjLXpzLUpLaHkzRVVFbVRxX2RhQl9iYW02Nmh4X0FkLUo2Uld5dzFBanM2MmptZFRnc2E3eFJTYXhoRjNnMHViMW13T2Z5SV81aUtMaG9QaVE5Z2dPWHNpdnlwQWpzYWVoM3B1SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics sets March 26 webcast on 2025 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNdWNwZmc4NE9xdU5DSktBSjlCdWFGLUpJaVlTWlhSc0RKTlJzMHRsNVZST1JDQnduTV9sMlZIWmJEY0NGZG5YNmpqM3puWDNsMW5LOEROZ1ppTzkwOTVOeFpZMlVNcEFHLWdGcFlrMTZFRDB2aGNIWkZ6bGpCMnhjVEhwb19ZYV9fZkZPR1MwZXFNbUU3SXB6NVlQVF9sTkhNWDJCVHVZTjBWa1ZEbzBfVERURFZiMXVzbnh0Rg?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cognition Therapeutics, Inc. Achieves 75% Enrollment in Phase 2 START Study for Early Alzheimer\u2019s Disease Treatment | CGTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQM2hNbllkckxRVG1rSVc5QVZHSnJvYk4zbDdnZVB0RmwtWWxhNDdpTXcybmdpYlVZeG9UOVJ0aVdRZ1hiVmxUcGFNTUM4STdLVFIwQW8wdWFxVmc2ZmJ5YjY0OUlUbGZWenR4aVdhdnJBcVluQmFGdWVDV0pPUm9hMXpHd09sTC1yQzM2Y3M5ZkxIc1ZXaDdZTGFWWUc5RkdRS3dMY0xFZ19GaXBkanpGZWZIcXd2SjZiUUN5a0pWSGltLWhObVZYWS1YUWU4NzB0ZEd6OEItb2R4OU5Eckw3dGR5WURaY29fSllFQkUxMUJzUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-09-03T07:00:00+00:00", "published_display": "03 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 52, "sentiment_summary": {"positive": 15, "negative": 4, "neutral": 33, "score": 57, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.4, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.09, "latest_week": "2026-07-10", "one_week_move": -6.8, "four_week_move": -9.9, "twelve_week_move": -8.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.611405, "market_dynamics_buy_signal": false, "relative_strength": -32.228248, "fair_value_gap": -11.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.0562, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.8% over one week, -9.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "GlobeNewswire", "count": 6}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.8% over one week, -9.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit"}], "updated_at": "2026-07-16T00:25:27.693700+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}